[1]
Mareel, M.; Leroy, A. Clinical, cellular, and molecular aspects of cancer invasion. Physiol. Rev., 2003, 83, 337-376.
[2]
Wesche, J.; Haglund, K.; Haugsten, E.M. Fibroblast growth factors and their receptors in cancer. Biochem. J., 2011, 437, 199-213.
[3]
Qiang, H.; Gu, W.; Huang, D.; Shi, W.; Qiu, Q.; Dai, Y.; Huang, W.; Qian, H. Design, synthesis and biological evaluation of 4-aminopyrimidine-5-cabaldehyde oximes as dual inhibitors of c-Met and VEGFR-2. Bioorg. Med. Chem., 2016, 24, 3353-3358.
[4]
Amin, K.M.; Barsoum, F.F.; Awadallah, F.M.; Mohamed, N.E. Identification of new potent phthalazine derivatives with VEGFR-2 and EGFR kinase inhibitory activity. Eur. J. Med. Chem., 2016, 123, 191-201.
[5]
Usifoh, C.; Scriba, G.K. Synthesis and anticonvulsant activity of acetylenic quinazolinone derivatives. Arch. Pharm., 2000, 333, 261-266.
[6]
Archana, V.; Srivastava, K.; Kumar, A. Synthesis of newer thiadiazolyl and thiazolidinonyl quinazolin-4(3H)- ones as potential anticonvulsant agents. Eur. J. Chem., 2002, 37, 873-882.
[7]
Based on our interest in synthetic and medicinal chemistry (g). Kaur, R.; Kapoor, Y.; Manjal, S.K.; Rawal, R.K.; Kumar, K. Diversity oriented synthetic approaches for furoindoline: A review. Curr. Org. Synth., 2019, 16(3), 342-368.
[8]
Kaur, R.; Chaudhary, S.; Kumar, K.; Gupta, M.K.; Rawal, R.K. Recent synthetic and medicinal perspectives of dihydropyrimidinones: A review. Eur. J. Med. Chem., 2017, 132, 108-134.